Intervention
Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownExamination of Ocular Surface Effects With Administration of Travatan Z and XALATANNCT00798759 · 2008-12-01
COMPLETEDPhase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthNCT00761319 · 2008-10-01
COMPLETEDTravatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionNCT00690794 · 2008-07-01
COMPLETEDEffects of Travatan Z and Xalatan on Ocular Surface HealthNCT00708422 · 2008-07-01
COMPLETEDA Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionNCT00527592 · 2007-05-01
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED5
Phase mix
PHASE43
PHASE32
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.